Introduction: Studies have shown the differential impact of the second surge of acute Covid-19 infection, across age, clinical outcome and ethnicity. How these factors impact the clinical characteristics and outcome of multisystem inflammatory syndrome in children (MIS-C) is largely unknown. Objectives: This hospital based comparative study was undertaken to analyse the clinical characteristics and outcomes of patients admitted with MIS-C during the two waves of Covid-19 infection in a tertiary care teaching hospital in South India. Method: Patients admitted between September 2020 and October 2021 with MIS-C were included in this study. Patient demographics, laboratory values and treatment details were compared between the two surges of COVID 19 related MIS-C.Results: Sixty-five children were admitted with MIS-C in the first wave and 73 in the second wave. More children were referred with a diagnosis of MIS-C in the second wave (p=0.001). There was no significant difference in the mean age or malefemale ratio between the two waves. A significantly higher proportion of children in the second wave had cervical lymphadenitis (p=0.02). Need for intensive care unit (ICU) admission (p<0.001), shock (p<0.001), respiratory support (p<0.001) and multiorgan involvement (p<0.001) were significantly lower in the second wave.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.